

General information about company		Standalone
Scrip code	540679	
NSE Symbol	SMSLIFE	
MSEI Symbol	NOTLISTED	
ISIN*	INE320X01016	
Name of company	SMS Lifesciences India Limited	
Type of company		
Class of security	Equity	
Date of start of financial year	01-04-2022	
Date of end of financial year	31-03-2023	
Date of board meeting when results were approved	29-05-2023	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-05-2022	
Description of presentation currency	INR	
Level of rounding used in financial results	Lakhs	
Reporting Quarter	Yearly	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited	Audited	
Segment Reporting	Single segment	
Description of single segment	Bulk Drugs / API's	
Start date and time of board meeting	29-05-2023 17:00	
End date and time of board meeting	29-05-2023 19:55	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2023	01-04-2022
B	Date of end of reporting period	31-03-2023	31-03-2023
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	6555.15	31524.18
	Other income	228.62	288.17
	<b>Total income</b>	<b>6783.77</b>	<b>31812.35</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	4088.48	18995.48
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-402.03	30.1
(d)	Employee benefit expense	898.08	3472.35
(e)	Finance costs	141.27	509.44
(f)	Depreciation, depletion and amortisation expense	211.68	817.3
<b>(f)</b>	<b>Other Expenses</b>		
1	Manufacturing Expenses	1283.01	4958.08
2	Other Expenses	435.16	1427.52
10			
	<b>Total other expenses</b>	<b>1718.17</b>	<b>6385.6</b>
	<b>Total expenses</b>	<b>6655.65</b>	<b>30210.27</b>

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2023	01-04-2022
B	Date of end of reporting period	31-03-2023	31-03-2023
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	128.12	1602.08
4	Exceptional items	235.16	235.16
<b>5</b>	<b>Total profit before tax</b>	363.28	1837.24
<b>7</b>	<b>Tax expense</b>		
8	Current tax	-75	350
9	Deferred tax	191.36	165.48
<b>10</b>	<b>Total tax expenses</b>	116.36	515.48
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	246.92	1321.76
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>21</b>	<b>Total profit (loss) for period</b>	246.92	1321.76

## Financial Results – Ind-AS

Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2023	01-04-2022
B	Date of end of reporting period	31-03-2023	31-03-2023
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Other comprehensive income [Abstract]</b>			
<b>1 Amount of items that will not be reclassified to profit and loss</b>			
	<b>Total Amount of items that will not be reclassified to profit and loss</b>		
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	-13.5	-7.04
<b>3 Amount of items that will be reclassified to profit and loss</b>			
	<b>Total Amount of items that will be reclassified to profit and loss</b>		
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	3.93	2.05
5	<b>Total Other comprehensive income</b>	9.57	4.99

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2023	01-04-2022
B	Date of end of reporting period	31-03-2023	31-03-2023
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	256.49	1326.75
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	302.33	302.33
	Face value of equity share capital	10	10
<b>27</b>	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		16558.89
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	8.17	43.72
	Diluted earnings (loss) per share from continuing operations	8.17	43.72
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	8.17	43.72
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	8.17	43.72
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
<b>33</b>	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

## Text Block

### Textual Information(1)

1. The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 29th May, 2023 and have been approved by the Board of Directors at its meeting held on 29th May, 2023. The statutory auditors of the Company have carried out an Audit of Standalone financial results for the quarter and year ended 31st March, 2023 and expressed an unmodified opinion thereon.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The figures for the current quarter and quarter ended 31st March, 2022 are balancing figures between audit figures of the full financial year ended 31st March, 2023 and 31st March, 2022 respectively, and the published year to date figures upto third quarter ended 31st December,2022 and 31st December, 2021 respectively.
- 4 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 Profit Before Tax of current year of Rs 1,837.24 Lakhs includes exceptional income of Rs 235.16 Lakhs as against Rs 1,269.22 Lakhs Exceptional Income of previous year out of Profit Before Tax of Rs.3,297.70 Lakhs.
- 6 The Board of Directors, at their meeting held on 29.05.2023, have recommended for payment of dividend of Rs.1.501- per share of Rs.10/- each, subject to approval of shareholders.
- 7 Figures for the previous period have been reclassified 1 regrouped wherever necessary to conform to current period's classification.

## Statement of Asset and Liabilities

Particulars		Current year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2022
Date of end of reporting period		31-03-2023
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	<b>Assets</b>	
<b>1</b>	<b>Non-current assets</b>	
	Property, plant and equipment	13783.36
	Capital work-in-progress	85.45
	Investment property	
	Goodwill	0
	Other intangible assets	7.54
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	<b>Non-current financial assets</b>	
	Non-current investments	2323.17
	Trade receivables, non-current	
	Loans, non-current	0
	Other non-current financial assets	261.67
	<b>Total non-current financial assets</b>	<b>2584.84</b>
	Deferred tax assets (net)	
	Other non-current assets	518.47
	<b>Total non-current assets</b>	<b>16979.66</b>
<b>2</b>	<b>Current assets</b>	
	Inventories	8046.22
	<b>Current financial asset</b>	
	Current investments	0
	Trade receivables, current	4551.88
	Cash and cash equivalents	15.14
	Bank balance other than cash and cash equivalents	80.29
	Loans, current	0
	Other current financial assets	
	<b>Total current financial assets</b>	<b>4647.31</b>
	Current tax assets (net)	34.42
	Other current assets	4031.34
	<b>Total current assets</b>	<b>16759.29</b>

<b>Statement of Asset and Liabilities</b>		
Particulars		Current year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2022
Date of end of reporting period		31-03-2023
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
<b>Total assets</b>		<b>33738.95</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
<b>Equity attributable to owners of parent</b>		
Equity share capital		302.33
Other equity		16100.47
<b>Total equity attributable to owners of parent</b>		<b>16402.8</b>
Non controlling interest		
<b>Total equity</b>		<b>16402.8</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Non-current financial liabilities</b>		
Borrowings, non-current		4597.02
Trade payables, non-current		
Other non-current financial liabilities		130.49
<b>Total non-current financial liabilities</b>		<b>4727.51</b>
Provisions, non-current		362.31
Deferred tax liabilities (net)		1189.74
Deferred government grants, Non-current		
Other non-current liabilities		
<b>Total non-current liabilities</b>		<b>6279.56</b>
<b>Current liabilities</b>		
<b>Current financial liabilities</b>		
Borrowings, current		3917.44
Trade payables, current		5452.54
Other current financial liabilities		712.65
<b>Total current financial liabilities</b>		<b>10082.63</b>
Other current liabilities		845.83
Provisions, current		128.13
Current tax liabilities (Net)		
Deferred government grants, Current		
<b>Total current liabilities</b>		<b>11056.59</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
<b>Total liabilities</b>		<b>17336.15</b>
<b>Total equity and liabilities</b>		<b>33738.95</b>
<b>Disclosure of notes on assets and liabilities</b>		



## Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-01-2023	01-04-2022
Date of end of reporting period	31-03-2023	31-03-2023
Whether accounts are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Standalone	Standalone
<b>1</b>	<b>Segment Revenue (Income)</b>	
	<b>(net sale/income from each segment should be disclosed)</b>	
	<b>Total Segment Revenue</b>	
	<b>Less: Inter segment revenue</b>	
	<b>Revenue from operations</b>	
<b>2</b>	<b>Segment Result</b>	
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>	
	<b>Total Profit before tax</b>	
	<b>i. Finance cost</b>	
	<b>ii. Other Unallocable Expenditure net off Unallocable income</b>	
	<b>Profit before tax</b>	
<b>3</b>	<b>(Segment Asset - Segment Liabilities)</b>	
	<b>Segment Asset</b>	
	<b>Total Segment Asset</b>	
	<b>Un-allocable Assets</b>	
	<b>Net Segment Asset</b>	
<b>4</b>	<b>Segment Liabilities</b>	
	<b>Segment Liabilities</b>	
	<b>Total Segment Liabilities</b>	
	<b>Un-allocable Liabilities</b>	
	<b>Net Segment Liabilities</b>	
	<b>Disclosure of notes on segments</b>	

## Cash flow statement, indirect

Particulars		Year ended (dd-mm-yyyy)
<b>A</b>	Date of start of reporting period	01-04-2022
<b>B</b>	Date of end of reporting period	31-03-2023
<b>C</b>	Whether results are audited or unaudited	Audited
<b>D</b>	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
	<b>Statement of cash flows</b>	
	<b>Cash flows from used in operating activities</b>	
	Profit before tax	1837.24
	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	1.78
	Adjustments for decrease (increase) in inventories	89.47
	Adjustments for decrease (increase) in trade receivables, current	-1225.75
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	473.39
	Adjustments for decrease (increase) in other non-current assets	75.87
	Adjustments for other financial assets, non-current	-33.38
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-1632.27
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	482.29
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	817.3
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	74.79
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	-46.57
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	24.11
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	-6.26
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	-953.45
	<b>Net cash flows from (used in) operations</b>	883.79
	Dividends received	0
	Interest paid	-350
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-1046.26
	<b>Net cash flows from (used in) operating activities</b>	187.53

	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	564.69
	Purchase of property, plant and equipment	3390.92
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	6.8
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	23.06
	<b>Net cash flows from (used in) investing activities</b>	<b>-2796.37</b>
	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	2980.71
	Repayments of borrowings	172.15
	Payments of finance lease liabilities	47.89
	Payments of lease liabilities	0
	Dividends paid	45.35
	Interest paid	185.98
	Income taxes paid (refund)	0

Other inflows (outflows) of cash	0
<b>Net cash flows from (used in) financing activities</b>	<b>2529.34</b>
<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>-79.5</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	
Effect of exchange rate changes on cash and cash equivalents	0
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>-79.5</b>
Cash and cash equivalents cash flow statement at beginning of period	94.64
<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>15.14</b>

## General information about company

Consolidated
--------------

Scrip code	540679
NSE Symbol	SMSLIFE
MSEI Symbol	NOTLISTED
ISIN*	INE320X01016
Name of company	SMS Lifesciences India Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2022
Date of end of financial year	31-03-2023
Date of board meeting when results were approved	29-05-2023
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-05-2022
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Audited
Segment Reporting	Single segment
Description of single segment	Bulk Drugs / API's
Start date and time of board meeting	29-05-2023 17:00
End date and time of board meeting	29-05-2023 19:55
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2023	01-04-2022
B	Date of end of reporting period	31-03-2023	31-03-2023
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	6373.14	31556.03
	Other income	245.56	307.25
	<b>Total income</b>	<b>6618.7</b>	<b>31863.28</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	3481.06	17132.7
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-355.22	7.52
(d)	Employee benefit expense	1144.97	4342.88
(e)	Finance costs	180.19	679.49
(f)	Depreciation, depletion and amortisation expense	292.44	1078.86
<b>(f)</b>	<b>Other Expenses</b>		
1	Manufacturing Expenses	1397.45	5660.07
2	Other Expenses	476.28	1537.63
10			
	<b>Total other expenses</b>	<b>1873.73</b>	<b>7197.7</b>
	<b>Total expenses</b>	<b>6617.17</b>	<b>30439.15</b>

## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2023	01-04-2022
B	Date of end of reporting period	31-03-2023	31-03-2023
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	1.53	1424.13
4	Exceptional items	235.16	235.16
<b>5</b>	<b>Total profit before tax</b>	236.69	1659.29
<b>7</b>	<b>Tax expense</b>		
8	Current tax	-75	350
9	Deferred tax	100.4	171.55
<b>10</b>	<b>Total tax expenses</b>	25.4	521.55
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	211.29	1137.74
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>21</b>	<b>Total profit (loss) for period</b>	211.29	1137.74

## Financial Results – Ind-AS

Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2023	01-04-2022
B	Date of end of reporting period	31-03-2023	31-03-2023
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Other comprehensive income [Abstract]</b>			
<b>1 Amount of items that will not be reclassified to profit and loss</b>			
	<b>Total Amount of items that will not be reclassified to profit and loss</b>		
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	-8.68	-3.58
<b>3 Amount of items that will be reclassified to profit and loss</b>			
	<b>Total Amount of items that will be reclassified to profit and loss</b>		
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	2.68	1.15
5	<b>Total Other comprehensive income</b>	6	2.43



## Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2023	01-04-2022
B	Date of end of reporting period	31-03-2023	31-03-2023
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	217.29	1140.17
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent	171.26	1146.29
	Total profit or loss, attributable to non-controlling interests	40.04	-9.57
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	302.33	302.33
	Face value of equity share capital	10	10
<b>27</b>	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		14920.9
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	5.66	37.92
	Diluted earnings (loss) per share from continuing operations	5.66	37.92
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	5.66	37.92
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	5.66	37.92
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
<b>33</b>	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

## Text Block

### Textual Information(1)

1. The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 29th May, 2023 and have been approved by the Board of Directors at its meeting held on 29th May, 2023. The statutory auditors of the Company have carried out Audit of Consolidated financial results for the quarter and year ended 31st March, 2023 and expressed an unmodified conclusion thereon.
2. The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The figures for the current quarter and quarter ended 31st March, 2022 are balancing figures between audit figures of the full financial year ended 31st March, 2023 and 31st March, 2022 respectively, and the published year to date figures upto third quarter ended 31st December, 2022 and 31st December, 2021 respectively.
4. The Consolidated financial results are prepared by applying Ind AS 110- "Consolidated Financial Statements", include the appropriate share of financial results of Mahi Drugs Private limited, a subsidiary with 60% stake.
5. The Consolidated entity is engaged in manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
6. Profit Before Tax of current year of Rs 1,659.29 Lakhs includes exceptional income of Rs 235.16 Lakhs as against Rs 1,269.22 Lakhs Exceptional Income of previous year out of Profit Before Tax of Rs.3,273.09 Lakhs.
7. The Board of Directors, at their meeting held on 29.05.2023, have recommended for payment of dividend of Rs. 1.50/- per share of Rs.10/- each, subject to approval of shareholders.
8. Figures for the previous period have been reclassified 1 regrouped wherever necessary to conform to current period's classification.

## Statement of Asset and Liabilities

	Particulars	Current year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2022
	Date of end of reporting period	31-03-2023
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Consolidated
	<b>Assets</b>	
<b>1</b>	<b>Non-current assets</b>	
	Property, plant and equipment	22657.69
	Capital work-in-progress	85.45
	Investment property	
	Goodwill	0
	Other intangible assets	7.53
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	<b>Non-current financial assets</b>	
	Non-current investments	3.61
	Trade receivables, non-current	
	Loans, non-current	0
	Other non-current financial assets	304.66
	<b>Total non-current financial assets</b>	<b>308.27</b>
	Deferred tax assets (net)	
	Other non-current assets	518.47
	<b>Total non-current assets</b>	<b>23577.41</b>
<b>2</b>	<b>Current assets</b>	
	Inventories	8623.49
	<b>Current financial asset</b>	
	Current investments	0
	Trade receivables, current	4606.11
	Cash and cash equivalents	127.78
	Bank balance other than cash and cash equivalents	313.5
	Loans, current	0
	Other current financial assets	
	<b>Total current financial assets</b>	<b>5047.39</b>
	Current tax assets (net)	51.8
	Other current assets	2188.97
	<b>Total current assets</b>	<b>15911.65</b>

## Statement of Asset and Liabilities

Particulars		Current year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2022
Date of end of reporting period		31-03-2023
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
<b>Total assets</b>		<b>39489.06</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
<b>Equity attributable to owners of parent</b>		
Equity share capital		302.33
Other equity		16558.9
<b>Total equity attributable to owners of parent</b>		<b>16861.23</b>
Non controlling interest		1960.44
<b>Total equity</b>		<b>18821.67</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Non-current financial liabilities</b>		
Borrowings, non-current		5494.18
Trade payables, non-current		
Other non-current financial liabilities		130.49
<b>Total non-current financial liabilities</b>		<b>5624.67</b>
Provisions, non-current		410.15
Deferred tax liabilities (net)		1276.14
Deferred government grants, Non-current		
Other non-current liabilities		
<b>Total non-current liabilities</b>		<b>7310.96</b>
<b>Current liabilities</b>		
<b>Current financial liabilities</b>		
Borrowings, current		4369.88
Trade payables, current		5966.76
Other current financial liabilities		1456.43
<b>Total current financial liabilities</b>		<b>11793.07</b>
Other current liabilities		1433.43
Provisions, current		129.93
Current tax liabilities (Net)		
Deferred government grants, Current		
<b>Total current liabilities</b>		<b>13356.43</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
<b>Total liabilities</b>		<b>20667.39</b>
<b>Total equity and liabilities</b>		<b>39489.06</b>
<b>Disclosure of notes on assets and liabilities</b>		

## Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-01-2023	01-04-2022
Date of end of reporting period	31-03-2023	31-03-2023
Whether accounts are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Consolidated	Consolidated
<b>1</b>	<b>Segment Revenue (Income)</b>	
	<b>(net sale/income from each segment should be disclosed)</b>	
	<b>Total Segment Revenue</b>	
	<b>Less: Inter segment revenue</b>	
	<b>Revenue from operations</b>	
<b>2</b>	<b>Segment Result</b>	
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>	
	<b>Total Profit before tax</b>	
	<b>i. Finance cost</b>	
	<b>ii. Other Unallocable Expenditure net off Unallocable income</b>	
	<b>Profit before tax</b>	
<b>3</b>	<b>(Segment Asset - Segment Liabilities)</b>	
	<b>Segment Asset</b>	
	<b>Total Segment Asset</b>	
	<b>Un-allocable Assets</b>	
	<b>Net Segment Asset</b>	
<b>4</b>	<b>Segment Liabilities</b>	
	<b>Segment Liabilities</b>	
	<b>Total Segment Liabilities</b>	
	<b>Un-allocable Liabilities</b>	
	<b>Net Segment Liabilities</b>	
	<b>Disclosure of notes on segments</b>	

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
<b>A</b>	Date of start of reporting period	01-04-2022
<b>B</b>	Date of end of reporting period	31-03-2023
<b>C</b>	Whether results are audited or unaudited	Audited
<b>D</b>	Nature of report standalone or consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory.	
	<b>Statement of cash flows</b>	
	<b>Cash flows from used in operating activities</b>	
	Profit before tax	1659.29
	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	2.89
	Adjustments for decrease (increase) in inventories	-28.08
	Adjustments for decrease (increase) in trade receivables, current	-1274.23
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-1781.69
	Adjustments for decrease (increase) in other non-current assets	129.6
	Adjustments for other financial assets, non-current	-33.38
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	1811.62
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	3759.12
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	1078.86
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	94.37
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	-46.57
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	24.11
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	-19.29
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	3669.11
	<b>Net cash flows from (used in) operations</b>	5328.4
	Dividends received	0
	Interest paid	-325.99
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-4184.89
	<b>Net cash flows from (used in) operating activities</b>	1469.5

	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	1694.78
	Purchase of property, plant and equipment	4855.09
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	19.82
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	11.34
	<b>Net cash flows from (used in) investing activities</b>	<b>-3129.15</b>
	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	2980.71
	Repayments of borrowings	846.06
	Payments of finance lease liabilities	47.9
	Payments of lease liabilities	0
	Dividends paid	45.35
	Interest paid	352.56
	Income taxes paid (refund)	0

	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) financing activities</b>	1688.84
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	29.19
	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0
	<b>Net increase (decrease) in cash and cash equivalents</b>	29.19
	Cash and cash equivalents cash flow statement at beginning of period	98.6
	<b>Cash and cash equivalents cash flow statement at end of period</b>	127.79